市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | ImageneBio, Inc. | 混合的 | - |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 2.7 |
| 技术平均移动指标 | 3.5 |
| 技术振荡指标 | -0.5 |
| 相对估值 | NA |
| 财务健康 | NA |
| 宏观环境 | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| 平均 | 0.58 |
|
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Bvf Inc/Il | 30 Jun 2026 | 1,110,002 |
| Blue Owl Capital Holdings Lp | 30 Jun 2026 | 917,692 |
| Omega Fund Management, Llc | 30 Jun 2026 | 455,361 |
| Trails Edge Capital Partners, Lp | 30 Jun 2026 | 282,004 |
| Monashee Investment Management Llc | 30 Jun 2026 | 192,344 |
该时间范围内无数据。
投资组合